Prognostic Value of the Systemic Immune-Inflammation Index in EGFR Mutation-Positive Lung Adenocarcinoma Patients Treated with Tyrosine Kinase Inhibitors
Downloads
Introduction: Inflammatory parameters calculated from complete blood counts such as neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and systemic immune-inflammatory index (SII) are related to poor prognosis in lung cancer patients. This study aimed to explore a correlation between NLR, PLR, and SII to survival rates in advanced lung adenocarcinoma with tyrosine kinase inhibitors (TKIs) as the main treatment choice.
Methods: This was a retrospective observational study of patients with epidermal growth factor receptor (EGFR) mutation-positive lung adenocarcinoma treated by TKIs at Ulin General Hospital Banjarmasin from January 2017 to December 2019. The optimal cut-off values for NLR, PLR, and SII were obtained using the receiver operating characteristic curve (ROC). Kaplan–Meier analyses were used to assess the prognostic value of inflammation parameters in overall survival (OS) and progression-free survival (PFS).
Results: This study involved 50 samples, 62% male, with an average age of 55.98 years old, 94% in stage IVA, EGFE mutation in exon 19 (58%) and exon 21 (42%). About 58% of patients have a smoking history. The optimal cut-off value for NLR, PLR, and SII was 6.095, 356.935, and 1767.0, respectively. However, only the SII was significantly associated with survival; SII ≥ 1767.0 correlated with shorter OS (18 months vs. 28 months, p = 0.014) and PFS (7 months vs. 12 months, p = 0.004).
Conclusion: Pre-treatment SII can be a prognostic factor for survival in EGFR mutation-positive lung adenocarcinoma patients receiving TKIs.
International Agency for Research on Cancer. Lung Fact Sheet. Geneva, (2020). [WebPage]
Duma N, Santana-Davila R, Molina J. Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. Mayo Clin Proc 2019; 94: 1623–1640. [PubMed]
Oh IJ, Hur JY, Park CK, et al. Clinical Activity of Pan-HER Inhibitors against HER2-Mutant Lung Adenocarcinoma. Clin Lung Cancer 2018; 19: e775–e781. [PubMed]
Zhang J, Yang GCH. Adenocarcinoma. In: Yang GCH, Ali SZ (eds) Lung and Mediastinum Cytohistology. Cambridge: Cambridge University Press, pp. 122–144.
Vyas P, Dudek M, Glazewski T, et al. A Case Study and Literature Review: Adenocarcinoma of the Lung. Cancer Ther Oncol Int J. Epub ahead of print 22 March 2017. [WebPage]
Haryati, Zubaidi M. Comparation of Citology Test and Plasma ctDNA for Detection of EGFR Mutation in Lung Adenocarcinoma at Ulin General Hospital Banjarmasin. Int J Respir Med 2019; 1: 52–59. [WebPage]
Deng C, Zhang N, Wang Y, et al. High Systemic Immune-Inflammation Index Predicts Poor Prognosis in Advanced Lung Adenocarcinoma Patients Treated with EGFR-TKIs. Medicine; 98, (2019). [WebPage]
Islas-Vazquez L, Aguilar D, Galicia-Velasco M, et al. IL-6, NLR, and SII Markers and Their Relation with Alterations in CD8+ T- Lymphocyte Subpopulations in Patients Treated for Lung Adenocarcinoma. Biology (Basel) 2020; 9: 376. [PubMed]
Corbeau I, Jacot W, Guiu S. Neutrophil to Lymphocyte Ratio as Prognostic and Predictive Factor in Breast Cancer Patients: A Systematic Review. Cancers (Basel) 2020; 12: 958. [PubMed]
Masucci MT, Minopoli M, Carriero MV. Tumor Associated Neutrophils. Their Role in Tumorigenesis, Metastasis, Prognosis and Therapy. Front Oncol; 9, (2019). [WebPage]
Biswas T, Kang K, Gawdi R, et al. Using the Systemic Immune-Inflammation Index (SII) as a Mid-Treatment Marker for Survival among Patients with Stage-III Locally Advanced Non-Small Cell Lung Cancer (NSCLC). Int J Environ Res Public Health 2020; 17: 7995. [PubMed]
Ozyurek BA, Ozdemirel TS, Ozden SB, et al. Prognostic Value of the Neutrophil to Lymphocyte Ratio (NLR) in Lung Cancer Cases. Asian Pacific Journal of Cancer Prevention 2017; 18: 1417–1421. [PubMed]
Yuan Y, Zhong H, Ye L, et al. Prognostic Value of Pretreatment Platelet Counts in Lung Cancer: A Systematic Review and Meta-Analysis. BMC Pulm Med 2020; 20: 96. [PubMed]
Guo W, Cai S, Zhang F, et al. Systemic Immune-Inflammation Index (SII) is Useful to Predict Survival Outcomes in Patients with Surgically Resected Non-Small Cell Lung Cancer. Thorac Cancer 2019; 10: 761–768. [PubMed]
Ju Q, Huang T, Zhang Y, et al. Systemic Immune-Inflammation Index Predicts Prognosis in Patients with Different EGFR-Mutant Lung Adenocarcinoma. Medicine; 100, (2021). [PubMed] [WebPage]
Singh N, Baby D, Rajguru JP, et al. Inflammation and Cancer. Ann Afr Med 2019; 18: 121–126. [PubMed]
Zhang Y, Sun Y, Zhang Q. Prognostic Value of the Systemic Immune-Inflammation Index in Patients with Breast Cancer: A Meta-Analysis. Cancer Cell Int 2020; 20: 224. [PubMed]
Bannaga AS, Tabuso M, Farrugia A, et al. C-Reactive Protein and Albumin Association with Mortality of Hospitalised SARS-CoV-2 Patients: A Tertiary Hospital Experience. Clin Med 2020; 20: 463. [PubMed]
Li B, Zhou P, Liu Y, et al. Platelet-to-Lymphocyte Ratio in Advanced Cancer: Review and Meta-Analysis. Clin Chim Acta 2018; 483: 48–56. [PubMed]
Li H, Wang G, Zhang H, et al. Prognostic Role of the Systemic Immune-Inflammation Index in Brain Metastases from Lung Adenocarcinoma with Different EGFR Mutations. Genes Immun 2019; 20: 455–461. [PubMed]
Tomita M, Ayabe T, Maeda R, et al. Systemic Immune-inflammation Index Predicts Survival of Patients after Curative Resection for Non-Small Cell Lung Cancer. In Vivo (Brooklyn) 2018; 32: 663. [PubMed]
Copyright (c) 2022 Marsheilla Riska, Haryati Haryati, Eko Suhartono
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions.
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution Share-Alike (CC BY-SA).
4. The Creative Commons Attribution Share-Alike (CC BY-SA) license allows re-distribution and re-use of a licensed work on the conditions that the creator is appropriately credited and that any derivative work is made available under "the same, similar or a compatible license”. Other than the conditions mentioned above, the editorial board is not responsible for copyright violation.
JR (